Literature DB >> 27746976

Relapsed small-cell lung cancer: platinum re-challenge or not.

Antonio Rossi1.   

Abstract

Entities:  

Year:  2016        PMID： 27746976      PMCID： PMC5059314          DOI： 10.21037/jtd.2016.09.28

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.

Authors:  Akira Inoue; Shunichi Sugawara; Makoto Maemondo; Yoshiaki Mori; Satoshi Oizumi; Masao Harada; Kageaki Taima; Naoto Morikawa; Takashi Ishida; Ichiro Kinoshita; Hiroshi Watanabe; Toshiro Suzuki; Taku Nakagawa; Ryota Saito; Toshihiro Nukiwa
Journal:  Lung Cancer       Date:  2015-05-04       Impact factor: 5.705

2.  Second-line chemotherapy for relapsed small cell lung cancer.

Authors:  N Ebi; K Kubota; Y Nishiwaki; F Hojo; T Matsumoto; R Kakinuma; H Ohmatsu; I Sekine; M Yokosaki; K Gotoh; H Yamamoto; T Kodama
Journal:  Jpn J Clin Oncol       Date:  1997-06       Impact factor: 3.019

3.  Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

Authors:  Andrea Ardizzoni; Marcello Tiseo; Luca Boni
Journal:  Eur J Cancer       Date:  2014-06-26       Impact factor: 9.162

Review 4.  Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice.

Authors:  Antonio Rossi; Olga Martelli; Massimo Di Maio
Journal:  Cancer Treat Rev       Date:  2012-10-18       Impact factor: 12.111

5.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors:  Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

6.  Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Authors:  Sayaka Onoda; Noriyuki Masuda; Takashi Seto; Kenji Eguchi; Yuichi Takiguchi; Hiroshi Isobe; Hiroaki Okamoto; Takashi Ogura; Akira Yokoyama; Nobuhiko Seki; Yoshiko Asaka-Amano; Masao Harada; Akihiro Tagawa; Hiroshi Kunikane; Masanori Yokoba; Kazutsugu Uematsu; Takayuki Kuriyama; Yumi Kuroiwa; Koshiro Watanabe
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

7.  Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.

Authors:  Giovenzio Genestreti; Marcello Tiseo; Hirotsugu Kenmotsu; Wakuda Kazushige; Monica Di Battista; Giovanna Cavallo; Federica Carloni; Alberto Bongiovanni; Marco Angelo Burgio; Claudia Casanova; Giulio Metro; Emanuela Scarpi; Taner Korkmaz; Seber Selcuk; Kurup Roopa; Raffaele Califano
Journal:  Clin Lung Cancer       Date:  2015-04-24       Impact factor: 4.785

8.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Authors:  E Beutler; T Gelbart; A Demina
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Authors:  Koichi Goto; Yuichiro Ohe; Taro Shibata; Takashi Seto; Toshiaki Takahashi; Kazuhiko Nakagawa; Hiroshi Tanaka; Koji Takeda; Makoto Nishio; Kiyoshi Mori; Miyako Satouchi; Toyoaki Hida; Naruo Yoshimura; Toshiyuki Kozuki; Fumio Imamura; Katsuyuki Kiura; Hiroaki Okamoto; Toshiyuki Sawa; Tomohide Tamura
Journal:  Lancet Oncol       Date:  2016-06-14       Impact factor: 41.316

10.  Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

Authors:  K Goto; I Sekine; Y Nishiwaki; R Kakinuma; K Kubota; T Matsumoto; H Ohmatsu; S Niho; T Kodama; T Shinkai; T Tamura; Y Ohe; H Kunitoh; N Yamamoto; H Nokihara; K Yoshida; T Sugiura; K Matsui; N Saijo
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640
View more
  2 in total

1.  Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.

Authors:  Yoshiko Naito; Kazuhiko Yamada; Yohei Imamura; Hidenobu Ishii; Norikazu Matsuo; Takaaki Tokito; Takashi Kinoshita; Koichi Azuma; Tomoaki Hoshino
Journal:  Med Oncol       Date:  2018-04-02       Impact factor: 3.064

2.  The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.

Authors:  Salomon Tendler; Lena Kanter; Rolf Lewensohn; Cristian Ortiz-Villalón; Kristina Viktorsson; Luigi De Petris
Journal:  PLoS One       Date:  2020-10-26       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.